| ²é¿´: 494 | »Ø¸´: 1 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
wqssfj1Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
|
[ÇóÖú]
ÇóÖú·Ò룡£¡£¡¼±£¡£¡£¡
|
|
|
The counts were each analyzed in a similar manner as the primary efficacy variable, by ANCOVA of the change from baseline, with baseline count as the covariate using mLOCF, with main effects of treatment group and medication-overuse strata. ҽѧͳ¼ÆÑ§Ïà¹ØÄÚÈÝ£¬¶àл£¡ |
» ²ÂÄãϲ»¶
070300»¯Ñ§Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
311Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
ÉúÎïѧµ÷¼Á
ÒѾÓÐ5È˻ظ´
269ר˶Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
08¹¤¿Æ 320×Ü·Ö Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
ѰÕÒµ÷¼Á
ÒѾÓÐ3È˻ظ´
291 Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤´óѧ070300 ѧ˶336Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Ò»Ö¾Ô¸¶«»ª´óѧ»¯Ñ§070300£¬Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
318Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
Ñô¹âÒÀ¾É
гæ (СÓÐÃûÆø)
- ·ÒëEPI: 4
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1269.9
- Ìû×Ó: 117
- ÔÚÏß: 11Сʱ
- ³æºÅ: 2009101
- ×¢²á: 2012-09-18
- רҵ: ÉúÎïÐÅϢѧ
2Â¥2012-09-25 10:10:10













»Ø¸´´ËÂ¥
40